Record Q1 FY27 Results, Explosive CDMO Growth, Higher Profitability and Bullish Brokerage Upgrades Drive Laurus Labs to New Lifetime High

Laurus Labs Ltd. has emerged as one of the biggest wealth creators in the Indian pharmaceutical sector in 2026, with its shares extending a spectacular rally after reporting a strong set of first-quarter earnings. The stock touched a fresh all-time high of ₹1,798 during Wednesday's intraday trade on the BSE, continuing its fourth consecutive session of gains. Investors cheered the company's record quarterly revenue, expanding operating margins, and robust growth in its high-value Contract Development and Manufacturing Organization (CDMO) business.

The remarkable rally has nearly doubled the company's share price since February, reflecting growing confidence in Laurus Labs' long-term transformation from a generic drug manufacturer into a global pharmaceutical manufacturing and innovation partner. The strong momentum has also elevated Laurus Labs ahead of Dr Reddy's Laboratories in terms of market capitalization, making it the eighth-largest listed pharmaceutical company in India.

Shares Nearly Double in Less Than Six Months

Laurus Labs has delivered one of the strongest performances among large-cap pharmaceutical stocks this year.

The company has witnessed:

• 97% appreciation from its February 2026 low of ₹913.25

• Nearly 20% gain during the past one month

• Around 15% rally over the last four trading sessions

• New lifetime high of ₹1,798

During the same period, the benchmark BSE Sensex has gained only around 1%, highlighting Laurus Labs' significant outperformance.

The sustained buying interest indicates that institutional investors are increasingly optimistic about the company's future earnings trajectory.

Laurus Labs Overtakes Dr Reddy's Laboratories

The sharp increase in Laurus Labs' valuation has resulted in a significant milestone for the company.

Its market capitalization has climbed to approximately ₹96,572 crore, marginally surpassing Dr Reddy's Laboratories, whose market value stands near ₹95,445 crore.

The latest rankings among India's listed pharmaceutical companies are led by:

The achievement reflects the market's confidence in Laurus Labs' evolving business model and improving profitability.

Q1 FY27 Delivers Record Financial Performance

The latest quarterly results exceeded market expectations across multiple parameters.

Key highlights include:

• Record quarterly revenue

• Significant expansion in EBITDA margins

• Improved profitability

• Strong operating cash generation

• Continued diversification of revenue sources

Management attributed the performance to broad-based growth across business segments, with the CDMO division emerging as the primary earnings driver.

The company has steadily reduced its dependence on traditional Anti-Retroviral (ARV) medicines while increasing its contribution from high-margin businesses.

CDMO Business Continues to Drive Growth

Laurus Labs' transformation into a global CDMO player is gathering pace.

The CDMO division reported robust growth driven by:

• Commercial manufacturing contracts

• Late-stage clinical development projects

• Partnerships with leading global pharmaceutical companies

• Strong demand across human healthcare

• Expansion into animal health

• Opportunities in crop science

Industry experts believe outsourcing by global pharmaceutical companies will continue to support long-term demand for Indian CDMO companies.

As multinational pharmaceutical firms increasingly diversify manufacturing beyond traditional markets, Laurus Labs appears well-positioned to capitalize on this structural opportunity.

Affordable Medicines Business Maintains Healthy Momentum

Apart from CDMO, Laurus Labs continues to strengthen its Affordable Medicines portfolio.

Growth during the quarter was supported by:

• Higher volumes in Anti-Retroviral therapies

• Strong oncology product sales

• New launches in regulated markets

• Better product mix

The gradual decline in ARV contribution to overall revenue has improved the company's earnings quality by increasing the share of higher-margin businesses.

Brokerages Turn More Optimistic

Following the robust quarterly performance, leading brokerage firms have upgraded their outlook on Laurus Labs.

InCred Equities

• Rating upgraded from Hold to Add

• Target price raised to ₹1,990

• Higher earnings estimates driven by CDMO growth

According to the brokerage, Laurus Labs is expected to achieve EBITDA margins of nearly 30% by FY28, supported by increasing contribution from high-value manufacturing contracts.

Motilal Oswal Financial Services

Motilal Oswal maintained its Buy recommendation with a target price of ₹1,980.

The brokerage expects:

• Earnings CAGR of around 24% during FY26-FY28

• Continued operating leverage

• Strong visibility in commercial manufacturing

• Healthy global order pipeline

The brokerage also highlighted Laurus Labs' investments in advanced manufacturing capabilities such as biologics and Antibody-Drug Conjugates (ADCs), which could become meaningful growth drivers over the next several years.

₹2,000 Crore Investment to Expand Capacity

To support future demand, Laurus Labs plans to invest approximately ₹2,000 crore during FY27.

The capital expenditure will be directed towards:

• Expanding CDMO manufacturing facilities

• Building a commercial-scale peptide manufacturing block in Visakhapatnam

• Enhancing biologics capabilities

• Developing differentiated pharmaceutical technologies

• Increasing production capacity for global customers

These investments are expected to strengthen Laurus Labs' competitive position in the global pharmaceutical outsourcing market.

Analysts Raise Earnings Forecasts

The strong first-quarter performance has prompted analysts to revise their earnings estimates upward.

Several research houses have increased FY27 and FY28 earnings projections after considering:

• Strong CDMO execution

• Higher operating margins

• Better product mix

• Capacity expansion

• New commercial contracts

• Improved operating leverage

The upward revisions reflect growing confidence that Laurus Labs' transformation strategy is translating into sustainable earnings growth.

What Makes Laurus Labs Different?

Unlike traditional generic pharmaceutical companies, Laurus Labs is increasingly focusing on high-value manufacturing services and specialty technologies.

Its diversified portfolio now includes:

• Active Pharmaceutical Ingredients (APIs)

• Finished Dosage Formulations (FDF)

• CDMO services

• Biologics

• Peptide manufacturing

• Antibody-Drug Conjugates (ADCs)

This diversified business model reduces dependence on any single product category while improving long-term revenue visibility.

Risks Investors Should Watch

Despite its impressive growth trajectory, investors should remain mindful of several risks:

• Rich valuations following the recent rally

• Execution risks in large capital expenditure projects

• Dependence on global pharmaceutical demand

• Regulatory inspections across manufacturing facilities

• Currency fluctuations affecting export revenue

• Competitive pricing in CDMO contracts

The pace of commercial execution will remain a key factor influencing future earnings.

Why the Pharma Sector Is in Focus

India's pharmaceutical sector continues to benefit from several structural tailwinds:

• Rising global outsourcing

• Increasing demand for complex drug manufacturing

• Expansion of biologics and specialty medicines

• Supply chain diversification by multinational pharmaceutical companies

• Growing healthcare spending worldwide

Companies with advanced manufacturing capabilities, regulatory approvals, and strong research expertise are expected to be among the biggest beneficiaries of these trends.

Key Highlights